An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)

Trial Profile

An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2018

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions
  • Acronyms PIONEER-OLE
  • Sponsors MyoKardia
  • Most Recent Events

    • 10 May 2018 According to a MyoKardia media release, first interim data are expected in the first quarter of 2019.
    • 10 May 2018 Status changed from not yet recruiting to recruiting, according to a MyoKardia media release.
    • 07 May 2018 Planned number of patients changed from 20 to 12.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top